Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MNKD files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMannKind raises $50M to fund $45M CVR payment triggered by Furoscix ReadyFlow FDA approval
Filed July 24, 2026 · Period ending July 23, 2026 · ~1 min read
Key Changes
-
high
FDA approved Furoscix ReadyFlow (furosemide injection) for treating edema in adults with heart failure or chronic kidney disease, opening a new revenue stream in cardiovascular and renal markets.
Item 8.01 verify on EDGAR → -
high
MannKind raised $50M gross proceeds via private placement of 10.4M common shares at $3.89 and pre-funded warrants for 2.4M shares at $3.88, representing ~12.9M shares of potential dilution.
Item 3.02 verify on EDGAR → -
high
Net proceeds will fund a $45M contingent value rights payment triggered by the Furoscix ReadyFlow approval and general corporate purposes.
Item 3.02 verify on EDGAR → -
medium
Pre-funded warrants carry a nominal $0.01 exercise price, never expire, and can be exercised cashless, making them effectively equivalent to common stock with a 19.99% beneficial ownership cap.
Item 3.02 verify on EDGAR → -
medium
MannKind committed to file a resale registration statement within 30 days, enabling investors to sell shares publicly once effective and potentially increasing near-term selling pressure.
Item 3.02 verify on EDGAR →
Summary
MannKind disclosed two linked events: the FDA approved Furoscix ReadyFlow for treating edema in adults with heart failure or chronic kidney disease, and the company raised $50 million in a private placement led by Frazier Life Sciences to fund the resulting $45 million contingent value rights payment.
The approval represents a regulatory milestone that opens a new commercial opportunity in cardiovascular and renal therapeutics, while simultaneously triggering a substantial cash obligation that the financing addresses. The private placement sold 10.4 million common shares at $3.89 and pre-funded warrants for 2.4 million shares at $3.88, representing approximately 12.9 million shares of potential dilution.
The pre-funded warrants have a nominal $0.01 exercise price and never expire, making them functionally equivalent to common stock. MannKind committed to register the shares for resale within 30 days, which may increase selling pressure once the registration becomes effective. The financing closed on July 24, 2026, providing the capital needed to satisfy the CVR payment while supporting general corporate purposes. Retail holders should monitor the commercial launch trajectory of Furoscix ReadyFlow to assess whether the new revenue stream justifies the dilution and whether the company can achieve profitability in the cardiovascular and renal markets without additional capital raises.
Section-by-Section Diff
Event · Exhibit 99.1
MannKind announces $50M private placement led by Frazier Life Sciences to fund FDA-triggered $45M contingent value rights payment.
Added in current filing · view on EDGAR →
MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that it has entered into a securities purchase agreement in connection with a private placement to certain institutional investors. The gross proceeds from the private placement financing are expected to be approximately $50 million.
MannKind entered into a securities purchase agreement for a private placement expected to raise approximately $50 million in gross proceeds from institutional investors. The financing is led by Frazier Life Sciences and is expected to close on or about July 24, 2026, subject to customary closing conditions.
Added in current filing · view on EDGAR →
MannKind intends to use the net proceeds for general corporate purposes, including funding the $45 million contingent value rights payment triggered by the recent FDA approval of Furoscix ReadyFlow™.
The company intends to use the net proceeds for general corporate purposes, including funding a $45 million contingent value rights payment that was triggered by the recent FDA approval of Furoscix ReadyFlow. This indicates a significant milestone payment obligation resulting from a regulatory approval.
Added in current filing · view on EDGAR →
Pursuant to the terms of the securities purchase agreement, MannKind is selling an aggregate of 10,440,838 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 2,412,632 shares of its common stock, at a purchase price of $3.89 per share and $3.88 per pre-funded warrant. The pre-funded warrants will have an exercise price of $0.01 per share and will be exercisable at any time after original issuance, subject to certain beneficial ownership limitations, and will not expire until exercised in full.
The private placement consists of 10,440,838 common shares at $3.89 per share and pre-funded warrants to purchase up to 2,412,632 shares at $3.88 per warrant. The pre-funded warrants have a nominal exercise price of $0.01 per share, are exercisable immediately after issuance, and do not expire until fully exercised. This structure represents potential dilution of approximately 12.9 million shares.
Added in current filing · view on EDGAR →
MannKind has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in the private placement and the shares of common stock issuable upon exercise of the pre-funded warrants.
MannKind has committed to file a registration statement with the SEC to register the resale of the common stock issued in the private placement and the shares issuable upon exercise of the pre-funded warrants. This will allow investors to resell their shares in the public market once the registration becomes effective.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 27, 2026 · How we verify